Trevi Therapeutics (TRVI) PT Lowered to $8 at Needham & Company

Go back to Trevi Therapeutics (TRVI) PT Lowered to $8 at Needham & Company

Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update

November 10, 2021 4:05 PM EST

NEW HAVEN, Conn., Nov. 10, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions, today announced financial results for the quarter ended September 30, 2021, as well as provided business updates.

... More

Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

November 9, 2021 7:30 AM EST

NEW HAVEN, Conn., Nov. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that senior leadership members will participate in a virtual fireside chat, as well as host investor meetings, at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021. Participants include Jennifer Good, President and CEO, Lisa Delfini, CFO, and Bill Forbes, CDO. Trevi's presentation is scheduled... More